

Australian Government

Department of Health

Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry: 65611 Agiofibe granules

ARTG entry for Medicine Listed

Sponsor SFI Australasia

Postal Address PO Box 1027, CROWS NEST, NSW, 1585

Australia

ARTG Start Date 31/07/1998

Product Category Medicine

Status Active

Approval Area Listed Medicines

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Agiofibe granules

Product Type Single Medicine Product Effective Date 2/11/2021

Permitted Indications

Maintain/support general health and wellbeing

Decrease/reduce/relieve constipation

Increase bowel movements by increasing stool bulk

Maintain/support bowel regularity by increasing stool bulk

Maintain/support bowel regularity

Decrease/reduce/relieve bowel discomfort

Maintain/support healthy bowel/colon function

Indication Requirements

Label statement: If symptoms persist, talk to your health professional.

Label statement: Drink plenty of water (or words to that effect).

Label statement: Do not use when abdominal pain, nausea or vomiting are present or if you develop diarrhoea. If you are pregnant or breastfeeding - seek the advice of a healthcare professional before taking this product (or words to that effect).

Product presentation must not refer to or imply weight loss

Label statement for stimulant laxatives: Prolonged use may cause serious bowel problems.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

(If medicine contains one sugar) contains [insert name of sugar] OR (If medicine contains two or more sugars) Contains sugars [or words to that effect].

Additional Product information

Pack Size/Poison information

Pack Size Poison Schedule

Page 1 of 2

Produced at 28.07.2022 at 03:41:36 AEST



Australian Government

Department of Health

Therapeutic Goods Administration

Components

1 . Formulation 1

Dosage FormGranulesRoute of AdministrationOral

Visual Identification

Active Ingredients

Ispaghula Husk Dry 22 mg/g
Plantago ovata seed Dry 650 mg/g

Other Ingredients (Excipients)

Acacia

Caraway Oil

hard paraffin

iron oxide red

iron oxide yellow

liquid paraffin

Peppermint Oil

purified talc

Sage Oil Spanish

sucrose

titanium dioxide

[©] Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.